Making sustainable medicines through eco-design Making sustainable medicines through eco-design Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
All the same, yet different – Ethnic Equality Month All the same, yet different – Ethnic Equality Month Mohammed Samy, Human Pharma Marketing Team Lead from Amsterdam explains how ethnic diversity creates collective strength and sustainable growth
The unseen lameness problem in horses The unseen lameness problem in horses Learn more about the signs, causes and preventive measures of lameness in horses.
equine asthma equine asthma Fighting Equine Asthma is a crucial step to improving the well-being of many horses worldwide. The right treatment can make a world of difference.
Chronic kidney disease in cats Chronic kidney disease in cats Detect and manage chronic kidney disease and high blood pressure in cats
Pet parasites are still here. What's the risk? Pet parasites are still here. What's the risk? What's the risk of pet parasites? They’re a growing challenge due to climate change. Check how to protect your dog and cat from fleas, ticks and more.
Breakthrough introduction innovation pet parasiticides Breakthrough introduction innovation pet parasiticides In 2014, Boehringer introduced a new product, which became the first in a new class of isoxazoline products for flea and tick protection in dogs.
Helping smallholder farmers after Covid-19 Helping smallholder farmers after Covid-19 In Ghana, we are helping smallholder farmers overcome hardship caused by the pandemic.
Our partners Bioveta Our partners Bioveta Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Collaborating for social impact Collaborating for social impact Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
Cooperation with The Defeat-NCD Partnership Cooperation with The Defeat-NCD Partnership Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Central Nervous System Diseases Central Nervous System Diseases Find out more about our research and development in central nervous system diseases
SPEVIGO® SPEVIGO® SPEVIGO® (spesolimab) is a novel, humanized, selective antibody for the treatment of generalized pustular psoriasis (GPP) flares.
Overcoming heartworm disease for homeless pets Overcoming heartworm disease for homeless pets Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine